Wechselwirkungen · Entecavir Viatris (previously Entecavir Mylan)
Entecavir Viatris 0.5 mg film-coated tablets Entecavir Viatris 1 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-226682 · Präparat HOS-217636
Since entecavir is predominantly eliminated by the kidney (see section 5.2), coadministration with medicinal products that reduce renal function or compete for active tubular secretion may increase serum concentrations of either medicinal product. Apart from lamivudine, adefovir dipivoxil and tenofovir disoproxil fumarate, the effects of coadministration of entecavir with medicinal products that are excreted renally or affect renal function have not been evaluated. Patients should be monitored closely for adverse reactions when entecavir is coadministered with such medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): adefovir dipivoxil (HOS-110478) entecavir (HOS-088124) lamivudine (HOS-085829) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-21T17:26:00Z · SHA-256 476e88e182a61cff080931eb3d25a9b1ea8071a3f7bd0270698d720fb6878752 · Passage ef6e707db8bf020283aef0686fde0997ef114b457c47c0f7e75e63cded1ae9f1 · Zeichen 0–591 im Abschnitt